MB-112

MB-112 is a preclinical-stage allogeneic chimeric antigen receptor (CAR) cell therapy being developed by March Biosciences. The therapy is generated using an induced pluripotent stem cell (iPSC) platform, which allows for the production of standardized, "off-the-shelf" therapeutic cells. This approach is intended to overcome the logistical and manufacturing challenges associated with patient-specific autologous CAR-T therapies, such as long turnaround times and high production costs. While the specific molecular target and primary clinical indications for MB-112 have not been publicly disclosed, the program leverages March Biosciences' focus on developing targeted immunotherapies for challenging hematological malignancies.

Other names

Allogeneic iPSC-derived CARallogeneic iPSC-CAR